Multi-Parameter Toxicity

Our Multi-Parameter Toxicity assay’s apply HUREL’s superior metabolic competency to a panel of complementary assays, creating a multi-parametric characterization of hepatotoxic risk.  HUREL Tox™  incorporates a 14-day, repeat-dose cytotoxicity study with both ATP and albumin (ELISA) readouts.

Cytotoxicity and Hepatotoxicity Screening

Our cytotoxicity and hepatotoxicity screening service makes early, high-acuity assessment of hepatotoxic risk cost-effective for smaller organizations and thereby brings new illumination to the challenge of reducing late-stage candidate attrition.

Metabolite Generation and ID

HUREL micro livers produce robust metabolite yields that closely correlate to metabolites generated by parent compounds in vivo.

Metabolic Clearance

The HUREL micro liver coculture system is a robust and reliable method for human in vivo clearance prediction and metabolite detection of slowly metabolized drugs.

Viral Liver Disease Modeling

The HUREL Viral™ platform aids the study of viral persistence and accelerates the development of antiviral drugs not just to mitigate recurring symptoms of but to fully cure chronic hepatitis B (HBV).

HUREL® Flux™

Hepatobiliary research services based on a new, patent-pending efflux transporter assay method.  Visikol’s HUREL primary hepatocyte co-cultures allow the hepatocytes to polarize and form stable and enduring biliary canaliculi networks and their associated transporters for over 30 days.